Navigation Links
New Executive Vice President Commercial Appointed
Date:5/15/2012

STOCKHOLM, May 15, 2012 /PRNewswire/ --

Medivir AB (OMX: MVIR), a research-based specialty pharmaceutical company focused on infectious diseases, announced today that it has appointed Henric Juserius to be the new head of the company's commercial activities. Henric, who will have overall responsibility for Medivir's pharmaceutical marketing and sales, will join the company in August 2012 and will be part of the management team.

Henric Juserius has a degree in business administration and most recently held the position as Commercial Director for the Nordic region at Actelion Pharmaceuticals. He has an extensive experience from the industry and has worked with pharmaceutical marketing and sales for more than 20 years in companies such as Astra, GlaxoWellcome, Pfizer, Serono and Actelion.

"I am very pleased to welcome Henric Juserius to Medivir as Executive Vice President, Commercial. His extensive experience and broad expertise in marketing and sales of prescription drugs from both large and small pharmaceutical companies will be invaluable now that Medivir is approaching a market launch in the Nordic countries of its flagship product for hepatitis C, TMC435. Henric will also work on the development of Medivir's existing portfolio of prescription drugs," says Maris Hartmanis, President and CEO of Medivir.


About Medivir

Medivir is an emerging research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company's key pipeline asset is TMC435, a novel protease inhibitor in phase III clinical development for hepatitis C that is being developed in collaboration with Janssen Pharmaceuticals.

In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia to ensure timely commercialisation of TMC435 in the Nordic markets, once approved.

Medivir's first product, the unique cold sore product Xerese®/Xerclear®, was launched on the US market in 2011. Xerese®/Xerclear®, which has been approved in both the US and Europe, is being launched in collaboration with GlaxoSmithKline to be sold OTC in Europe, Japan and Russia. Rights in North America, Canada and Mexico were sold to Meda AB in June 2011. Medivir has retained the Rx rights for Xerclear® in Sweden and Finland.

For more information on Medivir, please see the company's website:  http://www.medivir.com

 

For more information, please contact

Rein Piir, EVP Corporate Affairs & IR, Office line +46-8-440-6550 or Mobile +46-708-537292, Maris Hartmanis, CEO, +46-8-407-64-30


'/>"/>
SOURCE Medivir AB
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
3. Industry Executives Finding Value in Shift of Scientific Publications
4. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
5. Evalve Expands Executive Leadership Team
6. ParagonRx Names Ellen M. Derrico To Chief Marketing Executive Post
7. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
8. Premier Research Appoints Troy W. McCall, Ph.D. as Chief Executive Officer
9. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
10. Lincare Holdings Inc. Extends Terms of Employment Agreements with Executive Officers
11. Curemark Announces Senior Executive Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:10/2/2017)...  AllianceRx Walgreens Prime, the combined central specialty pharmacy ... benefit manager Prime Therapeutics LLC (Prime), today officially began ... unveiling of new signage at its headquarters in ... a few other company-owned facilities across the country. This ... of whom will begin to see the AllianceRx Walgreens ...
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
Breaking Medicine Technology:
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
Breaking Medicine News(10 mins):